mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients

Abstract

KLK14 mRNA expression merits further investigation as a potential prognostic biomarker of overall survival of patients with CLL.

Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer

“…Similar signatures consisting of miRNAs have been proposed in prostate cancer (59,60), laryngeal squamous cell carcinoma (61), and other human malignancies (62). Multiparametric panels of biomarkers could also integrate protein-coding transcripts produced by cancer-related genes such as the apoptosis-related genes BCL2L12 (63-67), BCL2 (68,69) and BAX (70,71), DDC (72)(73)(74)(75), transcription factors such as HIF1 (39), and/or other mRNAs with significant prognostic value in human malignancies (76)(77)(78)(79)(80)(81)(82)(83). Besides that, miRNAs can stably circulate in human body fluids (e.g., plasma, urine etc.…”

Alternative Splicing Detection Tool—a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis

“…To date, a lot of genes are known to express alternative splice variants, some of which may have significant clinical value (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27). The family of KLKs constitutes such a prominent example (28,29), as particular splice variants of the KLK1-KLK15 genes have been highlighted as putative biomarkers in human malignancies (30)(31)(32)(33)(34)(35). Very recently, ASDT has been used to partially reveal novel transcripts of tissue kallikrein (KLK1) (36) and several other members of the kallikrein-related peptidase (KLK) family (36)(37)(38)(39), as well as splice variants of the BCL2L12 gene (40,41), a prominent member of the apoptosis-related BCL2 family (42,43) with important prognostic value both in regard with solid tumors (44)(45)(46) as well as hematological malignancies (47,48), similarly to the major members of the BCL2 family, namely BCL2 and BAX (49)(50)(51).…”

A 3′ tRNA‐derived fragment produced by tRNALeuAAG and tRNALeuTAG is associated with poor prognosis in B‐cell chronic lymphocytic leukemia, independently of classical prognostic factors

“…Moreover, multivariate Cox regression analysis unveiled the independent prognostic significance of this tRF for B-CLL, suggesting the potential integration of tRF-Leu AAG/TAG in a multifactorial model, along with the currently established prognosticators. In the same direction, our research group intends to assess the prognostic significance of this molecule in a larger cohort of B-CLL patients, along with other promising molecular biomarkers, including HIF1A, 45 BCL2L12, 46 KLK14, 47 and/or particular miRNAs. 16 In conclusion, the aim of this study was to investigate the potential value of a tRF belonging to the tRF-3 group, as a prognostic and/ or screening biomarker for B-CLL.…”